Active Filter(s):
Details:
PneoVCA is designed to target certain proteins (neoantigens) on individuals’ tumor cells. Combination immunotherapy with mAB, such as pembrolizumab, may help the body’s immune system attack the cancer and thereby interfere with ability of tumor cells to grow and spread.
Lead Product(s): PneoVCA,Pembrolizumab
Therapeutic Area: Oncology Product Name: PneoVCA
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022